Login Register Cart 0
Generic placeholder image

Cardiovascular & Hematological Disorders-Drug Targets

Editor-in-Chief

ISSN (Print): 1871-529X
ISSN (Online): 2212-4063

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Atrial Fibrillation and Ventricular Tachyarrhythmias: Advancements for Better Outcomes

Author(s): Alireza Gheini, Afsoun Pourya and Ali Pooria*

Volume 20, Issue 4, 2020

Page: [249 - 259] Pages: 11

DOI: 10.2174/1871529X20666201001143907

Price: $65

Abstract

Cardiac arrhythmias are associated with several cardiac diseases and are prevalent in people with or without structural and valvular abnormalities. Ventricular arrhythmias (VA) can be life threating and their onset require immediate medical attention. Similarly, atrial fibrillation and flutter lead to stroke, heart failure and even death. Optimal treatment of VA is variable and depends on the medical condition associated with the rhythm disorder (which includes reversible causes such as myocardial ischemia or pro-arrhythmic drugs). While an implanted cardioverter defibrillator is often indicated in secondary prevention of VA. This review highlights the newest advancements in these techniques and management of ventricular and atrial tachyarrhythmias, along with pharmacological therapy.

Keywords: Cardiac arrhythmias, heart failure, atrial tachyarrhythmias, ventricular arrhythmias (VA), valvular abnormalities, myocardial ischemia.

« Previous Next »
Graphical Abstract

[1]
Tarhani, F.; Nezami, A. Role of probiotics in treatment of congenital heart disease and necrotizing enterocolitis. Pharm. Nut., 2019, 8, 100144.
[http://dx.doi.org/10.1016/j.phanu.2019.100144]
[2]
Methangkool, E.; Howard-Quijano, K.; Mahajan, A. Cardiac dysrhythmias: Understanding mechanisms, drug treatments, and novel therapies. Adv. Anesth., 2018, 36(1), 181-199.
[http://dx.doi.org/10.1016/j.aan.2018.07.008] [PMID: 30414637]
[3]
Pooria, A; Pourya, A; Gheini, A Postoperative complications associated with coronary artery bypass graft surgery and their therapeutic interventions. Future Cardiology., 2020, 16(5), 481-496.
[PMID: 32495650]
[4]
Williams, E.S.; Viswanathan, M.N. Current and emerging antiarrhythmic drug therapy for ventricular tachycardia. Cardiol. Ther., 2013, 2(1), 27-46.
[http://dx.doi.org/10.1007/s40119-013-0012-5] [PMID: 25135287]
[5]
Napolitano, C.; Priori, S.G. Genetics of ventricular tachycardia. Curr. Opin. Cardiol., 2002, 17(3), 222-228.
[http://dx.doi.org/10.1097/00001573-200205000-00003] [PMID: 12015470]
[6]
Grisanti, L.A. Diabetes and Arrhythmias: Pathophysiology, Mechanisms and Therapeutic Outcomes. Front. Physiol., 2018, 9, 1669.
[http://dx.doi.org/10.3389/fphys.2018.01669] [PMID: 30534081]
[7]
Pooria, A.; Pourya, A.; Gheini, A. Animal- and human-based evidence for the protective effects of stem cell therapy against cardiovascular disorders. J. Cell. Physiol., 2019, 234(9), 14927-14940.
[http://dx.doi.org/10.1002/jcp.28330] [PMID: 30811030]
[8]
Morillo, C.A.; Banerjee, A.; Perel, P.; Wood, D.; Jouven, X. Atrial fibrillation: The current epidemic. J. Geriatr. Cardiol., 2017, 14(3), 195-203.
[PMID: 28592963]
[9]
Cheraghi, M.; Pooria, A. A review: Nanofibrous scaffold in possible prevention and treatment of coronary artery disease. Biotechnol. Appl. Biochem., 2019, 66(4), 478-483.
[http://dx.doi.org/10.1002/bab.1750] [PMID: 30953379]
[10]
Jones, S; Lumens, J; Sohaib, SMA; Finegold, JA; Kanagaratnam, P.; Tanner, M. Cardiac resynchronization therapy: Mechanisms of action and scope for further improvement in cardiac function. Europace, 2017, 19(7), 1178-1186.
[11]
Jeon, D.S.; Park, J.S. Rapid and potent antiarrhythmic effect of cardiac resynchronization therapy in a patient with advanced dilated cardiomyopathy and a large ventricular arrhythmia burden. Korean Circ. J., 2017, 47(4), 523-527.
[http://dx.doi.org/10.4070/kcj.2016.0361] [PMID: 28765745]
[12]
Bristow, M.R.; Saxon, L.A.; Boehmer, J.; Krueger, S.; Kass, D.A.; De Marco, T.; Carson, P.; DiCarlo, L.; DeMets, D.; White, B.G.; DeVries, D.W.; Feldman, A.M. Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N. Engl. J. Med., 2004, 350(21), 2140-2150.
[http://dx.doi.org/10.1056/NEJMoa032423] [PMID: 15152059]
[13]
Salukhe, T.V.; Francis, D.P.; Sutton, R. Comparison of medical therapy, pacing and defibrillation in heart failure (COMPANION) trial terminated early; combined biventricular pacemaker-defibrillators reduce all-cause mortality and hospitalization. Int. J. Cardiol., 2003, 87(2-3), 119-120.
[http://dx.doi.org/10.1016/S0167-5273(02)00585-5] [PMID: 12559527]
[14]
Gold, M.R.; Linde, C.; Abraham, W.T.; Gardiwal, A.; Daubert, J.C. The impact of cardiac resynchronization therapy on the incidence of ventricular arrhythmias in mild heart failure. Heart Rhythm, 2011, 8(5), 679-684.
[http://dx.doi.org/10.1016/j.hrthm.2010.12.031] [PMID: 21185401]
[15]
Ruwald, M.H.; Solomon, S.D.; Foster, E.; Kutyifa, V.; Ruwald, A.C.; Sherazi, S.; McNitt, S.; Jons, C.; Moss, A.J.; Zareba, W. Left ventricular ejection fraction normalization in cardiac resynchronization therapy and risk of ventricular arrhythmias and clinical outcomes: Results from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) trial. Circulation, 2014, 130(25), 2278-2286.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.114.011283] [PMID: 25301831]
[16]
Doyle, C.L.; Huang, D.T.; Moss, A.J.; Solomon, S.D.; Campbell, P.; McNitt, S.; Polonsky, S.; Barsheshet, A.; Aktas, M.; Tompkins, C.; Zareba, W.; Goldenberg, I. Response of right ventricular size to treatment with cardiac resynchronization therapy and the risk of ventricular tachyarrhythmias in MADIT-CRT. Heart Rhythm, 2013, 10(10), 1471-1477.
[http://dx.doi.org/10.1016/j.hrthm.2013.07.029] [PMID: 23872690]
[17]
Maleki-Sadeghi, N.; Rahmani, P.; Aghsaeifard, Z.; Heidari, G. Effects of aminophylline on the levels of neutrophil gelatinase-associated lipocalin (NGAL) in asphyxiated term neonates. Arch. Physiol. Biochem., 2020, 1-6.
[http://dx.doi.org/10.1080/13813455.2020.1752259] [PMID: 32299251]
[18]
Lelakowski, J; Pudlo, J; Lelakowska-Piela, M; Rydlewska, A; Piekarz, J; Domaracki, D. Arrhythmia, device interventions and mortality analysis in patients with implanted cardioverter-defibrillator with/without resynchronisation therapy in dilative cardiomyopathy in primary prevention of sudden cardiac death. Polski merkuriusz lekarski : Organ Polskiego Towarzystwa Lekarskiego., 2016, 40(238), 216-222.
[19]
Daubert, J.C.; Martins, R.; Leclercq, C. Why we have to use cardiac resynchronization therapy-pacemaker more. Heart Fail. Clin., 2017, 13(1), 153-164.
[http://dx.doi.org/10.1016/j.hfc.2016.07.012] [PMID: 27886920]
[20]
Group, J.C.S.J.W. JCS Joint Working Group. Guidelines for Non-Pharmacotherapy of Cardiac Arrhythmias (JCS 2011). Circ. J., 2013, 77(1), 249-274.
[http://dx.doi.org/10.1253/circj.CJ-66-0054] [PMID: 23165786]
[21]
Abboud, J.; R Ehrlich, J. Antiarrhythmic drug therapy to avoid implantable cardioverter defibrillator shocks. Arrhythm. Electrophysiol. Rev., 2016, 5(2), 117-121.
[http://dx.doi.org/10.15420/AER.2016.10.2] [PMID: 27617090]
[22]
Corrado, D; Leoni, L; Link, MS; Bella, PD; Gaita, F; Curnis, A Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation., 2003, 108(25), 3084-3091.
[23]
Moss, A.J.; Zareba, W.; Hall, W.J.; Klein, H.; Wilber, D.J.; Cannom, D.S. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N. Engl. J. Med., 2002, 346(12), 877-883.
[24]
Køber, L.; Thune, J.J.; Nielsen, J.C.; Haarbo, J.; Videbæk, L.; Korup, E.; Jensen, G.; Hildebrandt, P.; Steffensen, F.H.; Bruun, N.E.; Eiskjær, H.; Brandes, A.; Thøgersen, A.M.; Gustafsson, F.; Egstrup, K.; Videbæk, R.; Hassager, C.; Svendsen, J.H.; Høfsten, D.E.; Torp-Pedersen, C.; Pehrson, S. DANISH Investigators. Defibrillator implantation in patients with nonischemic systolic heart failure. N. Engl. J. Med., 2016, 375(13), 1221-1230.
[http://dx.doi.org/10.1056/NEJMoa1608029] [PMID: 27571011]
[25]
Kiuchi, M.G.; Chen, S.; Pürerfellner, H. Incidence of ventricular arrhythmic events in CKD patients with ICD. Int. J. Cardiol., 2017, 227, 312-317.
[http://dx.doi.org/10.1016/j.ijcard.2016.11.094] [PMID: 27836294]
[26]
Washizuka, T.; Chinushi, M.; Kasai, H.; Watanabe, H.; Tagawa, M.; Hosaka, Y.; Abe, A.; Aizawa, Y. Inappropriate discharges from an intravenous implantable cardioverter defibrillator due to T-wave oversensing. Jpn. Circ. J., 2001, 65(7), 685-687.
[http://dx.doi.org/10.1253/jcj.65.685] [PMID: 11446507]
[27]
Fontenla, A.; Martínez-Ferrer, J.B.; Alzueta, J.; Viñolas, X.; García-Alberola, A.; Brugada, J.; Peinado, R.; Sancho-Tello, M.J.; Cano, A.; Fernández-Lozano, I. Incidence of arrhythmias in a large cohort of patients with current implantable cardioverter-defibrillators in Spain: Results from the UMBRELLA Registry. Europace, 2016, 18(11), 1726-1734.
[http://dx.doi.org/10.1093/europace/euv393] [PMID: 26705555]
[28]
Perini, A.P.; Kutyifa, V.; Veazie, P.; Daubert, J.P.; Schuger, C.; Zareba, W.; McNitt, S.; Rosero, S.; Tompkins, C.; Padeletti, L.; Moss, A.J. Effects of implantable cardioverter/defibrillator shock and antitachycardia pacing on anxiety and quality of life: A MADIT-RIT substudy. Am. Heart J., 2017, 189, 75-84.
[http://dx.doi.org/10.1016/j.ahj.2017.03.009] [PMID: 28625384]
[29]
Hess, P.L.; Al-Khatib, S.M.; Han, J.Y.; Edwards, R.; Bardy, G.H.; Bigger, J.T.; Buxton, A.; Cappato, R.; Dorian, P.; Hallstrom, A.; Kadish, A.H.; Kudenchuk, P.J.; Lee, K.L.; Mark, D.B.; Moss, A.J.; Steinman, R.; Inoue, L.Y.; Sanders, G. Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: Does age matter? An analysis of pooled data from 5 clinical trials. Circ. Cardiovasc. Qual. Outcomes, 2015, 8(2), 179-186.
[http://dx.doi.org/10.1161/CIRCOUTCOMES.114.001306] [PMID: 25669833]
[30]
Merchant, F.M.; Desai, Y.; Addish, M.A.; Kelly, K.; Casey, M.; Goyal, A.; Leon, A.R.; El-Chami, M.F. Implantable cardioverter-defibrillator placement for primary prevention in 2,346 patients: predictors of one-year survival. Tex. Heart Inst. J., 2018, 45(4), 221-225.
[http://dx.doi.org/10.14503/THIJ-17-6487] [PMID: 30374229]
[31]
Christensen, J.H.; Riahi, S.; Schmidt, E.B.; Mølgaard, H.; Kirstein Pedersen, A.; Heath, F.; Cosedis Nielsen, J.; Toft, E. n-3 Fatty acids and ventricular arrhythmias in patients with ischaemic heart disease and implantable cardioverter defibrillators. Europace, 2005, 7(4), 338-344.
[http://dx.doi.org/10.1016/j.eupc.2005.02.118] [PMID: 15944091]
[32]
Health Quality, O. Health quality ontario. remote monitoring of implantable cardioverter-defibrillators, cardiac resynchronization therapy and permanent pacemakers: A health technology assessment. Ont. Health Technol. Assess. Ser., 2018, 18(7), 1-199.
[PMID: 30443279]
[33]
Bardy, G.H.; Smith, W.M.; Hood, M.A.; Crozier, I.G.; Melton, I.C.; Jordaens, L. An Entirely Subcutaneous Implantable Cardioverter– Defibrillator. N. Engl. J .Med., 2010, 363(1), 36-44.
[34]
Theuns, DAMJ; Bhagwandien, RE; Szili-Torok, T Evaluation of recurrent ventricular tachyarrhythmias in patients who survived out-of-hospital cardiac arrest due to ventricular fibrillation: eligibility for subcutaneous implantable defibrillator therapy. J. Interv. Card. Electrophysiol., 2019, 55(3), 317-323.
[35]
Weiss, R.; Knight, B.P.; Gold, M.R.; Leon, A.R.; Herre, J.M.; Hood, M.; Rashtian, M.; Kremers, M.; Crozier, I.; Lee, K.L.; Smith, W.; Burke, M.C. Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. Circulation, 2013, 128(9), 944-953.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.113.003042] [PMID: 23979626]
[36]
Poole, J.E.; Gold, M.R. Who should receive the subcutaneous implanted defibrillator?: The subcutaneous implantable cardioverter defibrillator (ICD) should be considered in all ICD patients who do not require pacing. Circ. Arrhythm. Electrophysiol., 2013, 6(6), 1236-1244.
[http://dx.doi.org/10.1161/CIRCEP.113.000481] [PMID: 24347599]
[37]
Tanawuttiwat, T; Garisto, JD; Salow, A Protection from outpatient sudden cardiac death following ICD removal using a wearable cardioverter defibrillator. Pacing Clin. Electrophysiol., 2014, 37(5), 562-568.
[38]
Ellenbogen, K.A.; Koneru, J.N.; Sharma, P.S.; Deshpande, S.; Wan, C.; Szymkiewicz, S.J. Benefit of the wearable cardioverter- defibrillator in protecting patients after implantable-cardioverter defibrillator explant: Results from the national registry. JACC Clin. Electrophysiol., 2017, 3(3), 243-250.
[http://dx.doi.org/10.1016/j.jacep.2016.09.002] [PMID: 29759518]
[39]
Cuculich, P.S.; Schill, M.R.; Kashani, R.; Mutic, S.; Lang, A.; Cooper, D.; Faddis, M.; Gleva, M.; Noheria, A.; Smith, T.W.; Hallahan, D.; Rudy, Y.; Robinson, C.G. Noninvasive cardiac radiation for ablation of ventricular tachycardia. N. Engl. J. Med., 2017, 377(24), 2325-2336.
[http://dx.doi.org/10.1056/NEJMoa1613773] [PMID: 29236642]
[40]
Scholz, E.P.; Seidensaal, K.; Naumann, P.; André, F.; Katus, H.A.; Debus, J. Risen from the dead: Cardiac stereotactic ablative radiotherapy as last rescue in a patient with refractory ventricular fibrillation storm. HeartRhythm Case Rep., 2019, 5(6), 329-332.
[http://dx.doi.org/10.1016/j.hrcr.2019.03.004] [PMID: 31285992]
[41]
Vaseghi, M.; Barwad, P.; Malavassi Corrales, F.J.; Tandri, H.; Mathuria, N.; Shah, R.; Sorg, J.M.; Gima, J.; Mandal, K.; Sàenz Morales, L.C.; Lokhandwala, Y.; Shivkumar, K. Cardiac sympathetic denervation for refractory ventricular arrhythmias. J. Am. Coll. Cardiol., 2017, 69(25), 3070-3080.
[http://dx.doi.org/10.1016/j.jacc.2017.04.035] [PMID: 28641796]
[42]
Armaganijan, L.V.; Staico, R.; Moreira, D.A.; Lopes, R.D.; Medeiros, P.T.; Habib, R.; Melo Neto, J.; Katz, M.; Armaganijan, D.; Sousa, A.G.; Mahfoud, F.; Abizaid, A. 6-Month outcomes in patients with implantable cardioverter-defibrillators undergoing renal sympathetic denervation for the treatment of refractory ventricular arrhythmias. JACC Cardiovasc. Interv., 2015, 8(7), 984-990.
[http://dx.doi.org/10.1016/j.jcin.2015.03.012] [PMID: 26088516]
[43]
Yamaguchi, N.; Yamakawa, K.; Rajendran, P.S.; Takamiya, T.; Vaseghi, M. Antiarrhythmic effects of vagal nerve stimulation after cardiac sympathetic denervation in the setting of chronic myocardial infarction. Heart Rhythm, 2018, 15(8), 1214-1222.
[http://dx.doi.org/10.1016/j.hrthm.2018.03.012] [PMID: 29530832]
[44]
Martens, P.; Verbrugge, F.H.; Nijst, P.; Bertrand, P.B.; Dupont, M.; Tang, W.H.; Mullens, W. Feasibility and association of neurohumoral blocker up-titration after cardiac resynchronization therapy. J. Card. Fail., 2017, 23(8), 597-605.
[http://dx.doi.org/10.1016/j.cardfail.2017.03.001] [PMID: 28284756]
[45]
Birnie, D.H.; Healey, J.S.; Wells, G.A.; Ayala-Paredes, F.; Coutu, B.; Sumner, G.L.; Becker, G.; Verma, A.; Philippon, F.; Kalfon, E.; Eikelboom, J.; Sandhu, R.K.; Nery, P.B.; Lellouche, N.; Connolly, S.J.; Sapp, J.; Essebag, V. Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2). Eur. Heart J., 2018, 39(44), 3973-3979.
[http://dx.doi.org/10.1093/eurheartj/ehy413] [PMID: 30462279]
[46]
Voigt, A.; Shalaby, A.; Adelstein, E.; Saba, S. Beta-blocker utilization and outcomes in patients receiving cardiac resynchronization therapy. Clin. Cardiol., 2010, 33(7), E1-5.
[47]
Pooria, A.; Azadbakht, M.; Khoshdani-Farahani, P.; Pourya, A. Sigmoid volvulus after CABG surgery. Clin. Case Rep., 2020, 8(4), 606-611.
[http://dx.doi.org/10.1002/ccr3.2668] [PMID: 32274020]
[48]
Pietrasik, G.; Goldenberg, I.; McNitt, S.; Polonsky, B.; Moss, A.J.; Zareba, W. Efficacy of medical therapy for the reduction of heart failure events in patients with implanted cardioverter defibrillators. J. Cardiovasc. Electrophysiol., 2009, 20(4), 395-400.
[http://dx.doi.org/10.1111/j.1540-8167.2008.01333.x] [PMID: 19017351]
[49]
Massoullié, G.; Chouki, C.; Mulliez, A.; Rossignol, P.; Ploux, S.; Pereira, B.; Reuillard, A.; Jean, F.; Andronache, M.; Eschalier, A.; Motreff, P.; Clerfond, G.; Bordachar, P.; Authier, N.; Eschalier, R. Effect of optimization of medical treatment on long-term survival of patients with heart failure after implantable cardioverter defibrillator and cardiac resynchronization device implantation (from the French National EGB Database). Am. J. Cardiol., 2018, 121(6), 725-730.
[http://dx.doi.org/10.1016/j.amjcard.2017.12.013] [PMID: 29402420]
[50]
Schupp, T.; Behnes, M.; Weiß, C.; Nienaber, C.; Lang, S.; Reiser, L.; Bollow, A.; Taton, G.; Reichelt, T.; Ellguth, D.; Engelke, N.; Ansari, U.; El-Battrawy, I.; Bertsch, T.; Akin, M.; Mashayekhi, K.; Borggrefe, M.; Akin, I. Beta-blockers and ace inhibitors are associated with improved survival secondary to ventricular tachyarrhythmia. Cardiovasc. Drugs Ther., 2018, 32(4), 353-363.
[http://dx.doi.org/10.1007/s10557-018-6812-z] [PMID: 30074111]
[51]
Kahn, M.R.; Robbins, M.J.; Kim, M.C.; Fuster, V. Management of cardiovascular disease in patients with kidney disease. Nat. Rev. Cardiol., 2013, 10(5), 261-273.
[http://dx.doi.org/10.1038/nrcardio.2013.15] [PMID: 23419899]
[52]
Aghsaeifard, Z.; Alizadeh, R.; Bagheri, N. Association between neutrophil gelatinase-associated lipocalin (NGAL) and iron profile in chronic renal disease. Arch. Physiol. Biochem., 2020, 1-5.
[http://dx.doi.org/10.1080/13813455.2020.1720742] [PMID: 31994917]
[53]
Kowey, P.R. Pharmacological effects of antiarrhythmic drugs. Review and update. Arch. Intern. Med., 1998, 158(4), 325-332.
[http://dx.doi.org/10.1001/archinte.158.4.325] [PMID: 9487229]
[54]
Gojkovic, O.; Aliot, E.M.; Capucci, A.; Connolly, S.J.; Crijns, H.; Hohnloser, S.H.; Kulakowski, P.; Roy, D.; Radzik, D.; Singh, B.N.; Kowey, P.R. Celivarone in patients with an implantable cardioverter-defibrillator: Adjunctive therapy for the reduction of ventricular arrhythmia-triggered implantable cardioverter-defibrillator interventions. Heart Rhythm, 2012, 9(2), 217-224.e2.
[http://dx.doi.org/10.1016/j.hrthm.2011.09.073] [PMID: 21978965]
[55]
Connolly, S.J.; Dorian, P.; Roberts, R.S.; Gent, M.; Bailin, S.; Fain, E.S.; Thorpe, K.; Champagne, J.; Talajic, M.; Coutu, B.; Gronefeld, G.C.; Hohnloser, S.H. Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) Investigators. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA, 2006, 295(2), 165-171.
[http://dx.doi.org/10.1001/jama.295.2.165] [PMID: 16403928]
[56]
Watanabe, T.; Inoue, K.; Kashiwase, K.; Mine, T.; Hirooka, K.; Shutta, R.; Mizuno, H.; Okuyama, Y.; Sakata, Y.; Nanto, S. Differences in amiodarone efficacy in relation to ejection fraction and basal rhythm in patients with implantable cardioverter defibrillators. J. Electrocardiol., 2018, 51(6), 1111-1115.
[http://dx.doi.org/10.1016/j.jelectrocard.2018.10.083] [PMID: 30497740]
[57]
Schupp, T.; Behnes, M.; Reiser, L.; Bollow, A.; Taton, G.; Reichelt, T. Prognostic impact of beta-blocker compared to combined amiodarone therapy secondary to ventricular tachyarrhythmias. Int. J. Cardiol., 2019, 277, 118-124.
[58]
Alizadeh, R.; Aghsaie Fard, Z. Renal impairment and analgesia: From effectiveness to adverse effects. J. Cell. Physiol., 2019, 234(10), 17205-17211.
[http://dx.doi.org/10.1002/jcp.28506] [PMID: 30916404]
[59]
Priori, S.G.; Blomström-Lundqvist, C.; Mazzanti, A.; Blom, N.; Borggrefe, M.; Camm, J.; Elliott, P.M.; Fitzsimons, D.; Hatala, R.; Hindricks, G.; Kirchhof, P.; Kjeldsen, K.; Kuck, K.H.; Hernandez-Madrid, A.; Nikolaou, N.; Norekvål, T.M.; Spaulding, C.; Van Veldhuisen, D.J. ESC Scientific Document Group. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur. Heart J., 2015, 36(41), 2793-2867.
[http://dx.doi.org/10.1093/eurheartj/ehv316] [PMID: 26320108]
[60]
Hohnloser, S.H.; Dorian, P.; Roberts, R.; Gent, M.; Israel, C.W.; Fain, E.; Champagne, J.; Connolly, S.J. Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial. Circulation, 2006, 114(2), 104-109.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.106.618421] [PMID: 16818810]
[61]
Samanta, R.; Thiagalingam, A.; Turner, C.; Lakkireddy, D.J.; Kovoor, P. The use of intravenous sotalol in cardiac arrhythmias. Heart Lung Circ., 2018, 27(11), 1318-1326.
[http://dx.doi.org/10.1016/j.hlc.2018.03.017] [PMID: 29853342]
[62]
Alizadeh, R.; Fard, Z.A. Renal effects of general anesthesia from old to recent studies. J. Cell. Physiol., 2019, 234(10), 16944-16952.
[http://dx.doi.org/10.1002/jcp.28407] [PMID: 30843210]
[63]
Baquero, G.A.; Banchs, J.E.; Depalma, S.; Young, S.K.; Penny-Peterson, E.D.; Samii, S.M.; Wolbrette, D.L.; Naccarelli, G.V.; Gonzalez, M.D. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies. J. Cardiovasc. Electrophysiol., 2012, 23(3), 296-301.
[http://dx.doi.org/10.1111/j.1540-8167.2011.02183.x] [PMID: 21955243]
[64]
Bunch, T.J.; Mahapatra, S.; Murdock, D.; Molden, J.; Weiss, J.P.; May, H.T.; Bair, T.L.; Mader, K.M.; Crandall, B.G.; Day, J.D.; Osborn, J.S.; Muhlestein, J.B.; Lappe, D.L.; Anderson, J.L. Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks. Pacing Clin. Electrophysiol., 2011, 34(12), 1600-1606.
[http://dx.doi.org/10.1111/j.1540-8159.2011.03208.x] [PMID: 21895727]
[65]
Dorian, P.; Borggrefe, M.; Al-Khalidi, H.R.; Hohnloser, S.H.; Brum, J.M.; Tatla, D.S.; Brachmann, J.; Myerburg, R.J.; Cannom, D.S.; van der Laan, M.; Holroyde, M.J.; Singer, I.; Pratt, C.M. SHock Inhibition Evaluation with azimiLiDe (SHIELD) Investigators. Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. Circulation, 2004, 110(24), 3646-3654.
[http://dx.doi.org/10.1161/01.CIR.0000149240.98971.A8] [PMID: 15533855]
[66]
Martens, P.; Nuyens, D.; Rivero-Ayerza, M.; Van Herendael, H.; Vercammen, J.; Ceyssens, W.; Luwel, E.; Dupont, M.; Mullens, W. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction. Clin. Res. Cardiol., 2019, 108(10), 1074-1082.
[http://dx.doi.org/10.1007/s00392-019-01440-y] [PMID: 30788621]
[67]
Chen, Z.M.; Pan, H.C.; Chen, Y.P.; Peto, R.; Collins, R.; Jiang, L.X.; Xie, J.X.; Liu, L.S. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet, 2005, 366(9497), 1622-1632.
[http://dx.doi.org/10.1016/S0140-6736(05)67661-1] [PMID: 16271643]
[68]
Ibanez, B.; Macaya, C.; Sánchez-Brunete, V.; Pizarro, G.; Fernández-Friera, L.; Mateos, A.; Fernández-Ortiz, A.; García-Ruiz, J.M.; García-Álvarez, A.; Iñiguez, A.; Jiménez-Borreguero, J.; López-Romero, P.; Fernández-Jiménez, R.; Goicolea, J.; Ruiz-Mateos, B.; Bastante, T.; Arias, M.; Iglesias-Vázquez, J.A.; Rodriguez, M.D.; Escalera, N.; Acebal, C.; Cabrera, J.A.; Valenciano, J.; Pérez de Prado, A.; Fernández-Campos, M.J.; Casado, I.; García-Rubira, J.C.; García-Prieto, J.; Sanz-Rosa, D.; Cuellas, C.; Hernández-Antolín, R.; Albarrán, A.; Fernández-Vázquez, F.; de la Torre-Hernández, J.M.; Pocock, S.; Sanz, G.; Fuster, V. Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: The Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) trial. Circulation, 2013, 128(14), 1495-1503.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.113.003653] [PMID: 24002794]
[69]
Tan, Z.; Xiao, Z.; Wei, J.; Zhang, J.; Zhou, Q.; Smith, C.D.; Nani, A.; Wu, G.; Song, L.S.; Back, T.G.; Fill, M.; Chen, S.R. Nebivolol suppresses cardiac ryanodine receptor-mediated spontaneous Ca2+ release and catecholaminergic polymorphic ventricular tachycardia. Biochem. J., 2016, 473(22), 4159-4172.
[http://dx.doi.org/10.1042/BCJ20160620] [PMID: 27623776]
[70]
Peacock, A.; Ross, K. Pulmonary hypertension: a contraindication to the use of β-adrenoceptor blocking agents. Thorax, 2010, 65(5), 454-455.
[http://dx.doi.org/10.1136/thx.2008.111955] [PMID: 20435871]
[71]
Ghafarzadeh, M.; Shakarami, A.; Yari, F.; Namdari, P. The comparison of side effects of methyldopa, amlodipine, and metoprolol in pregnant women with chronic hypertension. Hypertens. Pregnancy, 2020, 39(3), 314-318.
[http://dx.doi.org/10.1080/10641955.2020.1766489] [PMID: 32420783]
[72]
Kargin, F.; Takir, H.B.; Salturk, C.; Goksenoglu, N.C.; Karabay, C.Y.; Mocin, O.Y.; Adiguzel, N.; Gungor, G.; Balci, M.K.; Yalcinsoy, M.; Kargin, R.; Karakurt, Z. The safety of beta-blocker use in chronic obstructive pulmonary disease patients with respiratory failure in the intensive care unit. Multidiscip. Respir. Med., 2014, 9(1), 8.
[http://dx.doi.org/10.1186/2049-6958-9-8] [PMID: 24495706]
[73]
Mackin, C.; DeWitt, E.S.; Black, K.J.; Tang, X.; Polizzotti, B.D.; van den Bosch, S.J. Intravenous amiodarone and sotalol impair contractility and cardiac output, but procainamide does not: A langendorff study. J. Cardiovasc. Pharmacol. Ther., 2018, 24(3), 288-297.
[PMID: 30497293]
[74]
Heidenreich, P.A.; Tsai, V.; Curtis, J.; Wang, Y.; Turakhia, M.P.; Masoudi, F.A.; Varosy, P.D.; Goldstein, M.K. A validated risk model for 1-year mortality after primary prevention implantable cardioverter defibrillator placement. Am. Heart J., 2015, 170(2), 281-289.e2.
[http://dx.doi.org/10.1016/j.ahj.2014.12.013] [PMID: 26299225]
[75]
Li, L.I.; Zhou, Y-L.; Zhang, X-J.; Wang, H-T. Successful treatment of cardiac electrical storm in dilated cardiomyopathy using esmolol: A case report. Exp. Ther. Med., 2016, 12(1), 107-110.
[http://dx.doi.org/10.3892/etm.2016.3281] [PMID: 27347024]
[76]
Scirica, B.M.; Morrow, D.A.; Hod, H.; Murphy, S.A.; Belardinelli, L.; Hedgepeth, C.M.; Molhoek, P.; Verheugt, F.W.; Gersh, B.J.; McCabe, C.H.; Braunwald, E. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation, 2007, 116(15), 1647-1652.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.107.724880] [PMID: 17804441]
[77]
Yang, P-C.; Moreno, J.D.; Miyake, C.Y.; Vaughn-Behrens, S.B.; Jeng, M-T.; Grandi, E.; Wehrens, X.H.; Noskov, S.Y.; Clancy, C.E. In silico prediction of drug therapy in catecholaminergic polymorphic ventricular tachycardia. J. Physiol., 2016, 594(3), 567-593.
[http://dx.doi.org/10.1113/JP271282] [PMID: 26515697]
[78]
Kirchhof, P.; Benussi, S.; Kotecha, D.; Ahlsson, A.; Atar, D.; Casadei, B.; Castella, M.; Diener, H.C.; Heidbuchel, H.; Hendriks, J.; Hindricks, G.; Manolis, A.S.; Oldgren, J.; Popescu, B.A.; Schotten, U.; Van Putte, B.; Vardas, P.; Agewall, S.; Camm, J.; Baron Esquivias, G.; Budts, W.; Carerj, S.; Casselman, F.; Coca, A.; De Caterina, R.; Deftereos, S.; Dobrev, D.; Ferro, J.M.; Filippatos, G.; Fitzsimons, D.; Gorenek, B.; Guenoun, M.; Hohnloser, S.H.; Kolh, P.; Lip, G.Y.; Manolis, A.; McMurray, J.; Ponikowski, P.; Rosenhek, R.; Ruschitzka, F.; Savelieva, I.; Sharma, S.; Suwalski, P.; Tamargo, J.L.; Taylor, C.J.; Van Gelder, I.C.; Voors, A.A.; Windecker, S.; Zamorano, J.L.; Zeppenfeld, K. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur. J. Cardiothorac. Surg., 2016, 50(5), e1-e88.
[http://dx.doi.org/10.1093/ejcts/ezw313] [PMID: 27663299]
[79]
Ellinor, P.T.; Lunetta, K.L.; Albert, C.M.; Glazer, N.L.; Ritchie, M.D.; Smith, A.V.; Arking, D.E.; Müller-Nurasyid, M.; Krijthe, B.P.; Lubitz, S.A.; Bis, J.C.; Chung, M.K.; Dörr, M.; Ozaki, K.; Roberts, J.D.; Smith, J.G.; Pfeufer, A.; Sinner, M.F.; Lohman, K.; Ding, J.; Smith, N.L.; Smith, J.D.; Rienstra, M.; Rice, K.M.; Van Wagoner, D.R.; Magnani, J.W.; Wakili, R.; Clauss, S.; Rotter, J.I.; Steinbeck, G.; Launer, L.J.; Davies, R.W.; Borkovich, M.; Harris, T.B.; Lin, H.; Völker, U.; Völzke, H.; Milan, D.J.; Hofman, A.; Boerwinkle, E.; Chen, L.Y.; Soliman, E.Z.; Voight, B.F.; Li, G.; Chakravarti, A.; Kubo, M.; Tedrow, U.B.; Rose, L.M.; Ridker, P.M.; Conen, D.; Tsunoda, T.; Furukawa, T.; Sotoodehnia, N.; Xu, S.; Kamatani, N.; Levy, D.; Nakamura, Y.; Parvez, B.; Mahida, S.; Furie, K.L.; Rosand, J.; Muhammad, R.; Psaty, B.M.; Meitinger, T.; Perz, S.; Wichmann, H.E.; Witteman, J.C.; Kao, W.H.; Kathiresan, S.; Roden, D.M.; Uitterlinden, A.G.; Rivadeneira, F.; McKnight, B.; Sjögren, M.; Newman, A.B.; Liu, Y.; Gollob, M.H.; Melander, O.; Tanaka, T.; Stricker, B.H.; Felix, S.B.; Alonso, A.; Darbar, D.; Barnard, J.; Chasman, D.I.; Heckbert, S.R.; Benjamin, E.J.; Gudnason, V.; Kääb, S. Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat. Genet., 2012, 44(6), 670-675.
[http://dx.doi.org/10.1038/ng.2261] [PMID: 22544366]
[80]
Meissner, A.; Maagh, P.; Christoph, A.; Oernek, A.; Plehn, G. Pulmonary vein potential mapping in atrial fibrillation with high density and standard spiral (lasso) catheters: A comparative study. J. Arrhythm., 2017, 33(3), 192-200.
[http://dx.doi.org/10.1016/j.joa.2016.10.562] [PMID: 28607614]
[81]
Syed, F.F.; DeSimone, C.V.; Friedman, P.A.; Asirvatham, S.J. Left atrial appendage exclusion for atrial fibrillation. Cardiol. Clin., 2014, 32(4), 601-625.
[http://dx.doi.org/10.1016/j.ccl.2014.07.006] [PMID: 25443240]
[82]
Hansen, B.J.; Zhao, J.; Csepe, T.A.; Moore, B.T.; Li, N.; Jayne, L.A.; Kalyanasundaram, A.; Lim, P.; Bratasz, A.; Powell, K.A.; Simonetti, O.P.; Higgins, R.S.; Kilic, A.; Mohler, P.J.; Janssen, P.M.; Weiss, R.; Hummel, J.D.; Fedorov, V.V. Atrial fibrillation driven by micro-anatomic intramural re-entry revealed by simultaneous sub-epicardial and sub-endocardial optical mapping in explanted human hearts. Eur. Heart J., 2015, 36(35), 2390-2401.
[http://dx.doi.org/10.1093/eurheartj/ehv233] [PMID: 26059724]
[83]
Klein, H.H.; Trappe, H-J. Cardioversion in non-valvular atrial fibrillation. Dtsch. Arztebl. Int., 2015, 112(50), 856-862.
[PMID: 26763380]
[84]
Amin, A.; Houmsse, A.; Ishola, A.; Tyler, J.; Houmsse, M. The current approach of atrial fibrillation management. Avicenna J. Med., 2016, 6(1), 8-16.
[http://dx.doi.org/10.4103/2231-0770.173580] [PMID: 26955600]
[85]
Morillo, C.A.; Verma, A.; Connolly, S.J.; Kuck, K.H.; Nair, G.M.; Champagne, J.; Sterns, L.D.; Beresh, H.; Healey, J.S.; Natale, A. RAAFT-2 Investigators. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): A randomized trial. JAMA, 2014, 311(7), 692-700.
[http://dx.doi.org/10.1001/jama.2014.467] [PMID: 24549549]
[86]
Scott, L.R. Antiarrhythmic drugs after ablation for atrial fibrillation: the hope, the hype, and the reality. Eur. Heart J., 2016, 37(7), 619-620.
[http://dx.doi.org/10.1093/eurheartj/ehv536] [PMID: 26450010]
[87]
Kuck, K-H.; Merkely, B.; Zahn, R.; Arentz, T.; Seidl, K.; Schlüter, M.; Tilz, R.R.; Piorkowski, C.; Gellér, L.; Kleemann, T.; Hindricks, G. Catheter ablation versus best medical therapy in patients with persistent atrial fibrillation and congestive heart failure: the randomized AMICA trial. Circ. Arrhythm. Electrophysiol., 2019, 12(12), e007731.
[http://dx.doi.org/10.1161/CIRCEP.119.007731] [PMID: 31760819]
[88]
Mujović, N.; Marinković, M.; Lenarczyk, R.; Tilz, R.; Potpara, T.S. Catheter ablation of atrial fibrillation: An overview for clinicians. Adv. Ther., 2017, 34(8), 1897-1917.
[http://dx.doi.org/10.1007/s12325-017-0590-z] [PMID: 28733782]
[89]
Haïssaguerre, M.; Sanders, P.; Hocini, M.; Takahashi, Y.; Rotter, M.; Sacher, F.; Rostock, T.; Hsu, L.F.; Bordachar, P.; Reuter, S.; Roudaut, R.; Clémenty, J.; Jaïs, P. Catheter ablation of long-lasting persistent atrial fibrillation: critical structures for termination. J. Cardiovasc. Electrophysiol., 2005, 16(11), 1125-1137.
[http://dx.doi.org/10.1111/j.1540-8167.2005.00307.x] [PMID: 16302892]
[90]
Anter, E.; Tschabrunn, C.M.; Josephson, M.E. High-resolution mapping of scar-related atrial arrhythmias using smaller electrodes with closer interelectrode spacing. Circ. Arrhythm. Electrophysiol., 2015, 8(3), 537-545.
[http://dx.doi.org/10.1161/CIRCEP.114.002737] [PMID: 25792508]
[91]
Sohns, C.; Saguner, A.M.; Lemes, C.; Santoro, F.; Mathew, S.; Heeger, C.; Reißmann, B.; Maurer, T.; Riedl, J.; Fink, T.; Hayashi, K.; Ouyang, F.; Kuck, K.H.; Metzner, A. First clinical experience using a novel high-resolution electroanatomical mapping system for left atrial ablation procedures. Clin. Res. Cardiol., 2016, 105(12), 992-1002.
[http://dx.doi.org/10.1007/s00392-016-1008-7] [PMID: 27289462]
[92]
Yagishita, A.; Gimbel, J.R.; DE Oliveira, S.; Manyam, H.; Sparano, D.; Cakulev, I.; Mackall, J.; Arruda, M. Long-term outcome of left atrial voltage-guided substrate ablation during atrial fibrillation: a novel adjunctive ablation strategy. J. Cardiovasc. Electrophysiol., 2017, 28(2), 147-155.
[http://dx.doi.org/10.1111/jce.13122] [PMID: 27862561]
[93]
Kottkamp, H.; Berg, J.; Bender, R.; Rieger, A.; Schreiber, D. Box Isolation of Fibrotic Areas (BIFA): A patient-tailored substrate modification approach for ablation of atrial fibrillation. J. Cardiovasc. Electrophysiol., 2016, 27(1), 22-30.
[http://dx.doi.org/10.1111/jce.12870] [PMID: 26511713]
[94]
Atienza, F.; Almendral, J.; Ormaetxe, J.M.; Moya, A.; Martínez-Alday, J.D.; Hernández-Madrid, A.; Castellanos, E.; Arribas, F.; Arias, M.Á.; Tercedor, L.; Peinado, R.; Arcocha, M.F.; Ortiz, M.; Martínez-Alzamora, N.; Arenal, A.; Fernández-Avilés, F.; Jalife, J. RADAR-AF Investigators. Comparison of radiofrequency catheter ablation of drivers and circumferential pulmonary vein isolation in atrial fibrillation: a noninferiority randomized multicenter RADAR-AF trial. J. Am. Coll. Cardiol., 2014, 64(23), 2455-2467.
[http://dx.doi.org/10.1016/j.jacc.2014.09.053] [PMID: 25500229]
[95]
Metzner, A.; Wissner, E.; Lin, T.; Ouyang, F.; Kuck, K-H. Balloon devices for atrial fibrillation therapy. Arrhythm. Electrophysiol. Rev., 2015, 4(1), 58-61.
[http://dx.doi.org/10.15420/aer.2015.4.1.58] [PMID: 26835102]
[96]
Lehmann, H.I.; Deisher, A.J.; Takami, M.; Kruse, J.J.; Song, L.; Anderson, S.E.; Cusma, J.T.; Parker, K.D.; Johnson, S.B.; Asirvatham, S.J.; Miller, R.C.; Herman, M.G.; Packer, D.L. External arrhythmia ablation using photon beams: Ablation of the atrioventricular junction in an intact animal model. Circ. Arrhythm. Electrophysiol., 2017, 10(4), e004304.
[http://dx.doi.org/10.1161/CIRCEP.116.004304] [PMID: 28408649]
[97]
Packer, D.L.; Kowal, R.C.; Wheelan, K.R.; Irwin, J.M.; Champagne, J.; Guerra, P.G.; Dubuc, M.; Reddy, V.; Nelson, L.; Holcomb, R.G.; Lehmann, J.W.; Ruskin, J.N. STOP AF Cryoablation Investigators. Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial. J. Am. Coll. Cardiol., 2013, 61(16), 1713-1723.
[http://dx.doi.org/10.1016/j.jacc.2012.11.064] [PMID: 23500312]
[98]
Canpolat, U.; Kocyigit, D.; Aytemir, K. Complications of atrial fibrillation cryoablation. J. Atr. Fibrillation, 2017, 10(4), 1620.
[http://dx.doi.org/10.4022/jafib.1620] [PMID: 29487676]
[99]
Kim, K.M.; Chung, S.; Kim, S.Y.; Kim, D.J.; Kim, J.S.; Lim, C.; Park, K.H. Comparison of radiofrequency ablation and cryoablation for the recovery of atrial contractility and survival. Korean J. Thorac. Cardiovasc. Surg., 2018, 51(4), 266-272.
[http://dx.doi.org/10.5090/kjtcs.2018.51.4.266] [PMID: 30109205]
[100]
Kuniss, M.; Greiß, H.; Pajitnev, D.; Akkaya, E.; Deubner, N.; Hain, A.; Bodammer, L.; Berkowitsch, A.; Chierchia, G.B.; Hamm, C.W.; Neumann, T. Cryoballoon ablation of persistent atrial fibrillation: Feasibility and safety of left atrial roof ablation with generation of conduction block in addition to antral pulmonary vein isolation. Europace, 2017, 19(7), 1109-1115.
[PMID: 27738068]
[101]
Yorgun, H.; Canpolat, U.; Kocyigit, D.; Çöteli, C.; Evranos, B.; Aytemir, K. Left atrial appendage isolation in addition to pulmonary vein isolation in persistent atrial fibrillation: one-year clinical outcome after cryoballoon-based ablation. Europace, 2017, 19(5), 758-768.
[http://dx.doi.org/10.1093/europace/eux005] [PMID: 28340073]
[102]
Lee, A.M.; Melby, S.J.; Damiano, R.J., Jr The surgical treatment of atrial fibrillation. Surg. Clin. North Am., 2009, 89(4), 1001-1020, x-xi.
[http://dx.doi.org/10.1016/j.suc.2009.06.001] [PMID: 19782848]
[103]
Stulak, JM; Dearani, JA; Daly, RC; Zehr, KJ; Sundt, TM, 3rd; Schaff, HV Left ventricular dysfunction in atrial fibrillation: Restoration of sinus rhythm by the Cox-maze procedure significantly improves systolic function and functional status. Ann Thorac Surg., 2006, 82(2), 494-500. discussion -1.
[http://dx.doi.org/10.1016/j.athoracsur.2006.03.075]
[104]
Ad, N.; Holmes, S.D.; Massimiano, P.S.; Pritchard, G.; Stone, L.E.; Henry, L. The effect of the Cox-maze procedure for atrial fibrillation concomitant to mitral and tricuspid valve surgery. J. Thorac. Cardiovasc. Surg., 2013, 146(6), 1426-1434.
[http://dx.doi.org/10.1016/j.jtcvs.2013.08.013] [PMID: 24075462]
[105]
Aghsaiefard, Z.; Hossenifard, Z.; Alizadeh, R.; Ramim, T. The relationship between hemoglobin level with PTH level and dialysis adequacy in chronic hemodialysis patients. Tehran Univ. Med. J., 2018, 76(4), 257-264.

Rights & Permissions Print Cite
Article Metrics
28
1
© 2024 Bentham Science Publishers | Privacy Policy